Korea United Pharmaceutical Incorporated operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Korea United Pharmaceutical Incorporated with three other
companies in this sector in KOREA (SOUTH) :
Samjin Pharmaceutical Company Limited
sales of 241.93 billion Korean Won [US$211.69 million]
of which 62%
Shin Poong Pharmaceutical Co., Ltd.
(189.72 billion Korean Won [US$166.01 million]
of which 73%
was Completed Medicine), and
Yungjin Pharm Co Ltd
(220.52 billion Korean Won [US$192.95 million]
of which 100%
was The manufacture and distribution of phar).
Korea United Pharmaceutical Incorporated reported sales of 221.31 billion Korean Won (US$193.65 million)
December of 2019.
increase of 4.4%
versus 2018, when the company's sales were 211.94 billion Korean Won .
Sales at Korea United Pharmaceutical Incorporated have increased during each of the previous five years
(and since 2014, sales have increased a total of 43%).
Sales of Glicetil saw an increase
that was more than double the company's growth rate: sales were up
32.9% in 2019, from
4.49 billion Korean Won to 5.97 billion Korean Won .
Korea United Pharmaceutical Incorporated also saw significant increases in sales in
Cilostan (up 10.5% to 35.81 billion Korean Won )
Anticancer Drug (up 8.1% to 23.71 billion Korean Won )
Castiin (up 16.6% to 19.29 billion Korean Won )
Not all segments of Korea United Pharmaceutical Incorporated experienced an increase in sales in 2019:
sales of Clanza fell 6.5% to 7.68 billion Korean Won .
(However, this segment's sales were only a very small portion of the company's overall sales).
Korea United Pharmaceutical Incorporated also experienced decreases in sales in
Othe Proucts (down 1.4% to 97.41 billion Korean Won )
Newbutin (down 1.2% to 6.27 billion Korean Won )
Omnihexol Inj. (down 0.9% to 6.07 billion Korean Won )